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Abstract
Background
Evidences linking treatment with inhibitors of gastric acid secretion (IGAS) and an increased
risk of serious infections are inconclusive, both in the population at large and in the particu-
lar case of patients with chronic kidney disease. We have undertaken an investigation to
disclose associations between treatment with IGAS and infectious outcomes, in patients
undergoing chronic Peritoneal Dialysis (PD).
Method
Observational, historic cohort, single center design. Six hundred and ninety-one patients
incident on PD were scrutinized for an association among treatment with IGAS (H2 antago-
nists H2A or proton pump inhibitors PPI) (main study variable), on one side, and the risks of
enteric peritoneal infection (main outcome), overall peritoneal infection, and general and
infectious mortality (secondary outcomes). We applied a three-step multivariate approach,
based on classic Cox models (baseline variables), time-dependent analyses and, when
appropriate, competing risk analyses.
Main results
The clinical characteristics of patients treated with H2A, PPI or none of these were signifi-
cantly different. Multivariate analyses disclosed a consistently increased risk of enteric peri-
tonitis in patients treated with IGAS (RR 1.65, 95% CI 1.08–2.55, p = 0.018, Cox). Stratified
analysis indicated that patients treated with H2A, rather than those on PPI, supported the
burden of this risk. Similar findings applied for the risk of infectious mortality. On the
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contrary, we were not able to detect any association among the study variables, on one
side, and the general risks of peritonitis or mortality, on the other.
Conclusions
Treatment with IGAS associates increased incidences of enteric peritonitis and infectious
mortality, among patients on chronic PD. The association is clear in the case of H2A but
less consistent in the case of PPI. Our results support the convenience of preferring PPI to
H2A, for gastric acid inhibition in PD patients.
Introduction
Inhibitors of gastric acid secretion (IGAS) are widely prescribed for prevention and manage-
ment of upper gastrointestinal tract disease, including gastroesophageal reflux, gastritis and
peptic ulcer. Treatment with this family of drugs has been associated with many side effects,
from minor manifestations (diarrhea, headache, flatulence. . .) to more consequential compli-
cations, including hypersensitivity reactions, nutritional deficits, bone marrow suppression,
bone fractures, neurotoxicity, hepatotoxicty and gastric tumors [1]. However, the significance
of some of these associations is questionable and, as a whole, IGAS are viewed as relatively safe
drugs.
Several recent reports have raised concerns about a potential risk of serious infections
among individuals treated with any of the two main groups of IGAS, namely H2 receptor
antagonists (H2A) and proton pump inhibitors (PPI). Pulmonary [2,3] and enteric infections,
including Clostridium difficile enterocolitis [4–6], could be particularly frequent, in these
patients. The mechanisms underlying this apparent predisposition are not totally clear, but col-
onization of the upper gastrointestinal tract by enteric bacteria, disruption of the natural com-
petence of the intestinal barrier, overgrowth of multirresistant bacteria or drug-induced
disorders affecting the bactericidal capacity of leukocytes have all been quoted as potential
explanations [5,7].
Patients with chronic kidney disease (CKD) are frequently treated with IGAS, due to the
high prevalence of gastrointestinal symptoms and disorders, which may be present in as much
as 70% of these individuals [8]. The incidence of upper gastrointestinal bleeding is also
markedly increased, in this setting [9]. The reasons underlying this predisposition are complex,
including the uremic milieu itself, comorbidity and polipharmacy, among other factors. The
association between treatment with IGAS and the risk of infection in patients with CKD has
been insufficiently investigated. In the particular case of patients undergoing chronic peritoneal
dialysis (PD), there is a specific concern that treatment with these drugs could promote perito-
neal infections by enteric bacteria, but the available studies are relatively small, suffer signifi-
cant methodologic limitations and have provided controversial results. We have undertaken a
better powered approach to this question, applying multivariate strategies of analysis, to con-
trol for expected imbalances among patients, regarding treatment with IGAS.
Method
General design
Following a longitudinal, historic cohort design, we investigated the association between treat-
ment with IGAS (main study variable) and selected outcomes of a relatively large sample of
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patients starting PD in a reference, university medical center during the period January 1995—
December 2013. Follow-up was closed by March 2015. The main outcome variable was the risk
of peritoneal infection by enteric bacteria (estimated as survival to first episode). Secondary
outcome variables included the overall risk of peritoneal infection, and the risks of general and
infectious mortality. We performed general analyses for the use of IGAS, and also in separate
for PPI and H2A. We applied univariate and multivariate strategies of analysis, including time-
dependent strategies and, when appropriate, a competing risk approach.
This study complied with the requirements of the local ethic committee of the University
Hospital of A Coruña (Spain) for retrospective, observational studies. Data were fully anon-
ymized for their management. Given the retrospective design of the study, neither written or
oral informed consent was requested form participant patients.
Study population
The study population included all patients starting PD in our centre between January 1995 and
December 2013 (follow-up closed by March 2015), under the following inclusion criteria:
• Age>10 years
• Minimum follow-up on PD of two months
• Clinical records available
• Information on treatment with IGAS available during follow-up
IGAS were generally prescribed for management of dyspepsia, prevention of gastroesopha-
geal disease (gastritis, peptic ulcer) or treatment of gastroesophageal reflux.
Study variables
The main study variable was treatment with IGAS, either managed as a binary variable or in
separate for PPI and H2A. We did not contemplate either the doses of IGAS prescribed or the
different drugs in each group. The overwhelming majority of patients were treated with the
PPI omeprazole or the H2A ranitidine.
The main outcome variable was the risk of peritoneal infection caused by enteric bacteria
(Enterobacteriaceae, Enterococcus spp. and/or enteric anaerobes), including polimicrobial
infections. We excluded cases with an overt surgical etiology. Secondary outcome variables
included the general risks of peritoneal infection and overall and infectious mortality.
Control variables included demographic data (age, gender), body mass index (Weight/
Height2), comorbidities [diabetes, Charlson’s comorbidity score, malnutrition (assessed by
standard subjective global assessment SGA, and managed as a binary variable), previous or cur-
rent immunosuppressive treatment and, specifically, background of previous atherothrombotic
events (coronary heart disease, thromboembolic stroke, aortic aneurism and/or peripheral vas-
cular disease demanding intervention or hospital admission)] and congestive heart failure, lab-
oratory variables [plasma albumin (autoanalyzer), hemoglobin (autonalyzer), C-reactive
protein (immunoturbidimetry)] and composite estimations, including glomerular filtration
rate GFR (mean of urea and creatinine renal clearances) and peritoneal transport characteris-
tics (D/P creatinine at 240’ during peritoneal equilibration test).
The use of ISAG increased progressively during the study period (40.1% of patients starting
PD 1995–2004 vs 64.8% of those starting 2005–2013). Moreover, more patients starting PD
before 2005 used H2A. For this reason, PD vintage was maintained as a control variable in
multivariate models, despite the fact that it did not perform as an independent predictor of any
of the outcome variables.
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Data analysis
Basic comparisons were produced according to Student’s t test, one-way ANOVA, Mann-
Whitney’s test and χ2 distribution analyses. We applied multivariate stepwise logistic regres-
sion analysis to disclose the main demographic, clinical and biochemical correlates of treat-
ment with IGAS. Univariate survival analyses for the main and secondary outcomes were
performed according to Kaplan Meier plots (log rank). Patients were censored in cases of loss
to follow-up, kidney transplant, drop-out to hemodialysis, death (peritoneal infection) or
non-infectious death (infectious mortality). Missing data were managed by pairwise deletion.
Baseline C-reactive protein values were available in only 560 patients (81.0%); but all the
other baseline control variables could be recorded in more than 97% of patients. Given the
expected imbalances among patients on different IGAS treatments, we also performed multi-
variate analyses, aimed at disclosing the adjusted risks for each outcome. We carried out this
in three steps
1. We first performed stepwise Cox analyses to investigate the association among baseline
treatment with PPI and H2A, on one side, and the outcome variables, on the other. Patients
were censored in the above mentioned cases. Only first-degree interactions were explored
for final models.
2. In a second step, we performed time-dependent Cox analyses, to take into account expected
variations in treatment with PPI and H2A and other variables, during follow-up. We fol-
lowed Murphy [10] and Fisher [11] models, for this purpose.
3. As a final step, we performed Fine and Grey competing risks analyses, to correct for the
potential distorting effects of mortality (overall) or non-infectious mortality on the associa-
tion among treatment with PPI/H2A, on one side, and the main outcome variables, on the
other. In these models, overall mortality was managed as a competing risk for peritoneal
infection (in case of peritonitis-related mortality the infection was recorded as an event pre-
vious to the demise), while non-infectious mortality was managed as a competing risk for
infectious mortality. Plots of accumulated incidences were produced according to Kalbe-
fleisch and Prentice.
We used the SPSS and Stata V10 softwares for data analysis.
Results
Six hundred and ninety-one patients fulfilled the inclusion criteria and were considered for
analysis. The demographic, clinical and laboratory characteristics of the patients showed signif-
icant differences, according to baseline treatment with IGAS (Table 1). Eight patients (3 on
H2A, 3 on PPI and 2 on none of the previous) presented advanced liver disease at the start of
PD. Multivariate, logistic regression analysis identified lower plasma albumin (odds ratio OR
0.93, 95% CI 0.90–0.96, p<0.0005), former or ongoing immunosuppressive therapy (OR 4.18,
95% CI 2.15–8.15, p<0.0005), a background of atherothrombotic events (OR 2.09, 95% CI
1.44–3.00, p<0.0005), older age (OR 1.02, 95% CI 1.01–1.03, p = 0.003), higher hemoglobin
levels (OR 1.12, 95% CI 1.01–1.25, p = 0.036), malnutrition (OR 1.76, 95% CI 1.13–2.75,
p = 0.013) and PD started 2005–2013 (OR 2.78, 95% CI 1.63–4.44, p<0.0005) as independent
correlates of treatment with IGAS (any type) at the initiation of PD. On the other hand, lower
plasma albumin (OR 0.95, 95% CI 0.90–0.99, p = 0.028), former or ongoing immunosuppres-
sive therapy (OR 3.25, 95% CI 1.32–7.80, p<0.0005) and PD started 2005–2013 (OR 4.58, 95%
CI 1.84–9.36, p<0.0005) were the main factors independently associated with prescription of
PPI rather than H2A, among patients treated with IGAS. On the other hand, the use of these
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drugs tended to increase during follow-up on PD, from 47% of patients, at baseline, to 69% at
the end of the second year (Fig 1).
Table 2 displays the main events and outcomes during follow-up (28.9 ± 24.4 months).
Only 15 patients (2.2%) were lost to follow-up due to transfer to another center. The global
incidence of peritonitis was 1 episode every 32.2 patient-months for patients on PPI at baseline,
as compared with 1/33.4 for patients on H2A and 1/36.2 for patients not treated with IGAS
(p = 0.33). Univariate (Kaplan-Meier) analyses displayed trends to an increased risk of enteric
Table 1. Baseline characteristics of the study population.
(N) PPI (207) H2A (119) None (366) p
Vintage (PD before 2005)(%) 64 (31.1) 87 (73.5) 255 (69.9) 0.0005
Age (years) 58.8 (16.0) 64.2 (13.7)* 57.4 (15.7) 0.0005
Gender (% males) 63.6 55.9 59.6 0.38
Diabetes (%) 85 (41.1) 44 (31.3) 117 (32.0) 0.40
Charlson’s score 4.4 (2.2) 4.4 (2.2) 3.6 (1.9)* 0.0005
Previous atherothrombotic event (%) 84 (40.6) 59 (50.0) 113 (30.9) 0.0005
Previous congestive heart failure (%) 54 (26.1) 36 (30.5) 49 (13.4) 0.0005
Modality of PD (% APD) 67 (32.4) 57 (48.3)* 135 (36.9) 0.016
Previous/Ongoing immunosuppression (%) 38 (18.4)* 8 (6.8) 16 (4.4) 0.0005
Malnutrition (%) 25 (12.1) 17 (14.4)* 25 (6.8) 0.009
GFR (mL/m) 6.7 (4.0)* 5.5 (3.7) 5.7 (3.6) 0.007
Body mass index (Kg/m2) 25.9 (4.7) 26.1 (4.7) 25.8 (4.4) 0.81
Plasma albumin (g/L) 35.5 (6.1) 36.3 (5.3) 38.1 (5.4)* 0.0005
Hemoglobin (g/dL) 10.7 (1.6) 10.6 (1.6) 10.3 (1.6) 0.055
C-reactive protein (mg/dL) 0.64(0.10, 52.4) 0.89 (0.10, 19.8) 0.53 (0.10, 16.7)** 0.016
D/P 240’ creatinine 0.67 (0.13) 0.66 (0.13) 0.65 (0.14) 0.39
PPI: Proton pump inhibitors; H2A: H2 receptor antagonists; APD: Automated PD; GFR: Glomerular ﬁltration rate
Figures denote mean values (SD) for numerical variables, median (range) for C-reactive protein and n (%) for categorical variables. Comparisons by
ANOVA (Scheffé), χ2 distribution and Mann Whitney’s test.
* Signiﬁcant difference vs any other group.
** Signiﬁcant difference vs H2A
doi:10.1371/journal.pone.0148806.t001
Fig 1. Proportion of patients treated with different types of inhibitors of gastric acid secretion during
the first two years of follow-up on PD (p<0.0005).
doi:10.1371/journal.pone.0148806.g001
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peritonitis (Fig 2a) and infectious mortality (Fig 2b) for patients treated with H2A (but not
PPI) at the initiation of PD. On the contrary, no such association was observed for the overall
risks of peritonitis (p = 0.22, log rank) or mortality (p = 0.18).
Table 3 presents the results of multivariate analysis for the main outcome variables, accord-
ing to baseline variables. Patients on IGAS presented a definitely increased risk of enteric peri-
tonitis during follow-up. Stratified analysis revealed that this risk was overt only for patients on
H2A, while the trend for patients on PPI did not reach statistical significance. Infectious mor-
tality was increased only in patients on H2A therapy, while we did not observe any association
among treatment with IGAS, on one side, and general mortality or overall risk of peritonitis,
on the other. Neither did we detect any significant interaction among treatment with IGAS, on
one side, and control variables, on the other.
Table 4 displays the results of multivariate, time-dependent analyses. Overall, the results
were quite similar to those observed for baseline variables although, in this case, the specific
risk of enteric peritonitis for patients on H2A did not reach statistical significance.
Fig 3a and 3b display Kalbefleisch-Prentice plots of competing risks for enteric peritonitis
and infectious mortality, respectively. Table 5 shows the results of competing risk analysis for
the main outcome variables, with trends similar to the other two multivariate approaches.
Treatment with IGAS associated a trend to an increased risk of enteric peritonitis, and a defi-
nite risk of infectious mortality, particularly in patients on H2A therapy.
Table 2. Main outcomes according to baseline treatment with inhibitors of gastric acid secretion.
PPI (n = 207) H2A (n = 118) None (n = 366)
Death 86 (41.5) 73 (61.9) 159 (43.4)
Cardiovascular 45 (21.7) 30 (25.4) 76 (20.8)
Infectious 17 (8.2) 25 (21.2) 33 (9.0)
Failure to thrive-PD suspended 10 (4.8) 8 (6.8) 14 (3.8)
Neoplasia 3 (1.4) 1 (0.8) 10 (2.7)
Other 11 (5.3) 9 (7.6) 26 (7.1)
Causes of infectious mortality
Peritoneal infection 8 17 19
Pulmonary infection 3 1 11
Bacterial endocarditis 1 0 0
Urinary tract infection 0 2 0
Biliary tract infection 0 2 0
Septicaemia (other/unknown origin) 3 4 1
Other 1 0 0
Peritonitis (patients suffering at least one episode) 117 (56.5) 70 (59.3) 191 (52.2)
Peritonitis (number of episodes) 181 (100) 108 (100) 289 (100)
Grampositives 87 (48.1) 52 (48.1) 143 (49.5)
Gramnegatives 35 (19.3) 26 (24.1) 47 (16.3)
Polimicrobial 26 (14.4) 13 (12.0) 45 (15.6)
Fungal (primary) 6 (3.3) 5 (4.6) 13 (4.5)
Mycobacteria 0 0 1 (0.3)
Negative culture 27 (14.9) 12 (11.1) 40 (13.8)
Enteric peritonitis ( 1 episode) 41 (19.8) 30 (25.4) 61 (16.7)
PPI: Proton pump inhibitors; H2A: H2 receptor antagonists
Figures denote number of patients (% versus total number of patients) except for the etiologic agents of peritonitis (number of episodes)
doi:10.1371/journal.pone.0148806.t002
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Discussion
Our results are consistent with the hypothesis that patients on PD who are treated with IGAS
present increased risks for enteric peritonitis and infectious mortality. There are several poten-
tial explanations for these associations. First, sustained inhibition of gastric acid secretion alters
Fig 2. (a). Survival to first episode of enteric peritonitis according to baseline treatment with IGAS (b) Survival to infectious mortality according to baseline
treatment with IGAS.
doi:10.1371/journal.pone.0148806.g002
Table 3. Impact of baseline treatment with inhibitors of gastric acid secretion on study outcomes. Multivariate
HR 95% CI p Control variables
Enteric peritonitis Age, Immunosuppression, GFR, C reactive protein
IGAS overall 1.65 1.08, 2.55 0.018
PPI 1.61 0.98, 2.51 0.059
H2A 1.67 1.02, 2.80 0.042
Infectious mortality Age, diabetes, Charlson, albumin, Immunossuppresion, GFR
IGAS overall 1.09 0.65, 1.82 0.75
PPI 0.68 0.35, 1.32 0.26
H2A 1.78 1.01, 3.21 0.049
Overall peritonitis Age, albumin, immunosuppression, GFR, modality of PD
IGAS overall 1.18 0.95, 1.47 0.11
PPI 1.23 0.96, 1.59 0.10
H2A 1.08 0.80, 1.47 0.61
Overall mortality Age, diabetes, Charlson, albumin, immunossuppresion, GFR
IGAS overall 0.96 0.76, 1.23 0.76
PPI 0.85 0.64, 1.13 0.26
H2A 1.15 0.85, 1.55 0.37
IGAS: Inhibitors of gastric acid secretion; PPI: Proton pump inhibitors; H2A: H2 receptor antagonists.
* Independent predictors of outcome in best model. PD vintage NS
Stepwise Cox models. Figures denote adjusted hazard ratios (HR) with 95% conﬁdence intervals and p values for the main outcome variables.
doi:10.1371/journal.pone.0148806.t003
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Table 4. Impact of treatment with inhibitors of gastric acid secretion on study outcomes. Time dependent, multivariate analysis.
HR 95% CI p Control variables
Enteric peritonitis Diabetes, Charlson, albumin, immunosuppression, hemoglobin, GFR
IGAS overall 1.33 1.02, 1.75 0.040
PPI 1.08 0.70, 1.66 0.74
H2A 1.45 0.92, 2.29 0.11
Infectious mortality Age, diabetes, Charlson, albumin, immunosuppression, hemoglobin, GFR
IGAS overall 1.61 1.14, 2.27 0.007
PPI 0.90 0.52, 1.49 0.62
H2A 2.03 1.19, 3.47 0.01
Overall peritonitis Age, albumin, immunosuppression, GFR, hemoglobin, modality of PD
IGAS overall 1.09 0.95, 1.60 0.24
PPI 1.32 0.95, 1.66 0.17
H2A 0.97 0.74, 1.26 0.80
Overall mortality Age, diabetes, Charlson, albumin, immunosuppression, hemoglobin, GFR
IGAS overall 1.11 0.93, 1.31 0.24
PPI 0.94 0.76, 1.29 0.94
H2A 1.16 0.88, 1.53 0.31
IGAS: Inhibitors of gastric acid secretion; PPI: Proton pump inhibitors; H2A: H2 receptor antagonists.
* Independent predictors of outcome in best model. PD vintage NS
Time dependent Cox’s models. Figures denote adjusted hazard ratios (HR) with 95% conﬁdence intervals and p values for the main outcome variables.
doi:10.1371/journal.pone.0148806.t004
Fig 3. (a). Competing risk plot for enteric peritonitis) competing event, death for any cause) (b) Competing risk plot for infectious mortality (competing event
death for noninfectious causes)
doi:10.1371/journal.pone.0148806.g003
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the bacterial ecology of the gastrointestinal tract, not just favoring gastric colonization by
enteric bacteria [12], but also modifying the flora of the lower gut [13]. Secondly, both hypo-
chlorhydria and bacterial overgrowth may facilitate microbial translocation across the intesti-
nal barrier. Thirdly, experimental studies have suggested that suppression of gastric acid
production may selectively promote colonization of the large intestine by pathogenic, multirre-
sistant bacteria [14]. Finally, IGAS may have detrimental effects on the bactericidal capacity of
neutrophils [15]. The potential clinical consequences could be increased incidences of enteric
infections [4], including Clostridium difficile enterocolitis, and pulmonary infections [7]. Some
specific subsets of patients could sustain a particularly high risk of suffering these complica-
tions, including cirrhotics with ascites [16,17] and hospitalized patients on antibiotic therapy
[6]. CKD may also represent a high risk setting, because the intestinal barrier and the micro-
biota of these patients are frequently altered [18], and treatment with IGAS could further com-
plicate these disorders.
PD may represent a particularly high risk setting for treatment with IGAS, due to the spe-
cific risk of peritoneal infections in these patients. Few studies have investigated the infectious
risk associated with IGAS among patients on PD. Caravaca et al [19] presented the results of
an observational survey on a group of 55 patients treated with PD, with the aim of disclosing
predictors of enteric peritonitis. Logistic regression analysis identified treatment with either
H2A or PPI as the only consistent predictor of this complication. On the contrary, del Peso
et al [20] were unable to detect such association in a sample of a similar size (n = 57). In 2008,
Nessim et al [21] presented the results of a case-control analysis of 228 episodes of peritonitis
in 134 PD patients, comparing factors associated with enteric versus non-enteric peritonitis.
Treatment with IGAS did not make any difference among groups, although stratified analyses
disclosed a trends to an association between H2A therapy and infections by enteric microbia.
A more recent case-control analysis on 120 patients [22] suggested an increased incidence of
peritonitis (overall), but not of enteric peritonitis, among patients treated with H2A.
The results of our study appear to support previous reports [21,22], suggesting that any
association between treatment with IGAS and peritoneal infections in PD patients may be
largely restricted to patients treated with H2A, while the evidence linking treatment with PPI
Table 5. Impact of treatment with inhibitors of gastric acid secretion on study outcomes. Competing risks analysis.
HR 95% CI p Control variables*
Enteric peritonitis Diabetes, Charlson, albumin, immunosuppression, hemoglobin, GFR
IGAS overall 1.51 1.00, 2.28 0.052
PPI 1.11 0.79, 2.65 0,62
H2A 1.40 0.90, 2.18 0.14
Infectious mortality Age, diabetes, Charlson, albumin, immunosuppression, hemoglobin, GFR
IGAS overall 1.35 0.98, 1.88 0.081
PPI 0.58 0.32, 1.02 0.066
H2A 2.25 1.36, 3.70 0.0015
Overall peritonitis Age. albumin, immunosuppression, GFR, hemoglobin, Modality of PD
IGAS overall 1.20 0.97, 1.51 0.09
PPI 1.20 0.95, 1.52 0.12
H2A 1.04 0.80, 1.35 0.76
IGAS: Inhibitors of gastric acid secretion; PPI: Proton pump inhibitors; H2A: H2 receptor antagonists.
* Independent predictors of outcome in best model. PD vintage NS
Competing events: Overall mortality (overall and enteric peritonitis) and non-infectious mortality (Infectious mortality)
doi:10.1371/journal.pone.0148806.t005
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and these infections was much less consistent. At first sight, this difference is difficult to
explain, because both types of IGAS appear to carry similar side effects predisposing to infec-
tion. It is possible that treatment with H2A may associate unidentified, additional risks not
present in the case of PPI. For instance, Kwon et al [22] have suggested that the prolonged
half-life of H2A, but not of PPI, in the presence of CKD [23] could promote some of the nega-
tive effects of these drugs, in this setting.
This study has significant limitations. The observational, nonrandomized design does not
permit to establish a causality link between treatment with IGAS and outcomes. Moreover, the
significant differences among patients, according to treatment with these drugs (Table 1), may
raise the possibility that IGAS may just be a confounding factor for other, unknown variables.
The fact that the specific indications for starting IGAS were not clear in many cases may add
further uncertainty. To correct for these potential biases, we applied three different multivariate
strategies of analysis, controlling for all the main variables related to outcomes, obtaining simi-
lar results. Remarkably, we observed no association among treatment with IGAS, on one side,
and the general risks of peritonitis or mortality, on the other, suggesting a specific association
to infectious events related to gastrointestinal bacteria. On the other hand, our study provides
the best powered evidence on this question published to date, permitting effective multivariate
approaches to data analyses, and providing consistent answers to the main questions under
consideration.
In summary, treatment with IGAS associates increased incidences of enteric peritonitis and
infectious mortality among patients treated with chronic PD. This association is clear in the
case of H2A, but much less consistent in the case of PPI. Our results support the convenience
of preferring PPI to H2A for gastric acid inhibition or, at least, to use lower doses of H2A, in
these patients. Only a randomized study may be able to establish a causal link among these
factors.
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